Development of candidemia on caspofungin therapy: A case report

C. Cheung, Y. Guo, P. Gialanella, Marta Feldmesser

Research output: Contribution to journalArticlepeer-review

45 Scopus citations


Caspofungin, an echinocandin, is approved for use in invasive candidiasis. Few cases of break-through candidal infections during caspofungin therapy have been reported and none have involved Candida parapsilosis. Here, we report a patient who developed multiple post-operative complications after pancreaticoduodenectomy for a pancreatic mass, including fungemia due to C. parapsilosis, while on caspofungin for treatment of Candida glabrata peritonitis. The fungemia resolved after a central venous catheter was removed and therapy was switched from caspofungin to amphotericin B lipid complex. Studies of C. parapsilosis susceptibility and the pharmacodynamics and drug interactions of caspofungin that may contribute to breakthrough fungemia are discussed.

Original languageEnglish (US)
Pages (from-to)345-348
Number of pages4
Issue number6
StatePublished - Dec 1 2006

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Development of candidemia on caspofungin therapy: A case report'. Together they form a unique fingerprint.

Cite this